铂抗肿瘤药物-大环化合物给药体系的研究进展  

Research progress of the drug delivery system of antitumor platinum drugs with macrocyclic compounds

作　　者：高传柱[1,2,3] 张艳[1] 陈骥[1] 费凡[1] 王天帅[1] 杨波[1] 董鹏[2,3] 张英杰[2,3] 

机构地区：[1]昆明理工大学生命科学与技术学院,云南昆明650500 [2]昆明理工大学材料科学与工程学院,云南昆明650500 [3]云南省先进电池及材料工程实验室,云南昆明650500

出　　处：《药学学报》2015年第6期650-657,共8页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(21361014;21302074;21062009);教育部博士点基金资助项目(20125314120007);云南省自然科学基金资助项目(人培)(KKSY201226108)

摘　　要：铂类抗肿瘤药物因其独特的作用机制、广泛的抗癌谱成为目前临床治疗恶性肿瘤最为有效的药物之一。但其毒副作用、耐药性或交叉耐药性、靶向性不明确等问题,成为了限制其扩大临床应用的障碍。超分子化学给药体系以其良好的安全性和低毒性逐渐受到人们的关注。超分子大环化合物与铂类抗肿瘤配合物形成的包合物或键接物增强了铂类药物的水溶性、稳定性和安全性,并因其具有潜在的肿瘤组织、器官靶向性成为了铂类抗肿瘤药物研发领域的热点之一。本文主要介绍了近年来三代超分子化学主体大环类化合物冠醚、环糊精、葫芦脲和杯芳烃与铂类抗肿瘤药物构建新型给药体系的研究进展。Platinum-based anticancer drugs have been becoming one of the most effective drugs for clinical treatment of malignant tumors for its unique mechanism of action and broad range of anticancer spectrum. But, there are still several problems such as side effects, drug resistance/cross resistance and no-specific targeting, becoming obstacles to restrict its expanding of clinical application. In recent years, supramolecular chemistry drug delivery systems have been gradually concerned for their favorable safety and low toxicity. Supramolecular macrocycles-platinum complexes increased the water solubility, stability and safety of traditional platinum drugs, and have become hot focus of developing novel platinum-based anticancer drugs because of its potential targeting of tumor tissues/organs. This article concentrates in the research progress of the new drug delivery system between platinum-based antieancer drugs with three generations of macrocycles： crown ether, cyclodextrin, cucurbituril and calixarene.

关 键 词：铂配合物 抗肿瘤 大环类超分子化合物 给药体系 

分 类 号：R979.1[医药卫生—药品]